RBC Capital lowered the firm’s price target on Bausch Health (BHC) to $10 from $11 and keeps a Sector Perform rating on the shares ahead of its Q4 results. The firm is adjusting its model as it reduces the BLCO – Bausch + Lomb – sale scenario, weighting to 60% from 75% given the recent news of Blackstone (BX) likely dropping out of consortium with TPG to take out BLCO, the analyst tells investors in a research note.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHC:
- Bausch Health’s XIFAXAN Selected for Medicare Price Negotiation
- Bausch Health acknowledges XIFAXAN selection for Medicare Negotiation Program
- Ozempic, Xtandi among next 15 drugs selected for U.S. price talks
- Bausch Health, George Medicines sign exclusive licensing agreement or GMRx2
- Bausch Health says Bausch + Lomb sale exploration process ‘ongoing’